BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26820131)

  • 21. Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia.
    Reuter CW; Krauter J; Onono FO; Bunke T; Damm F; Thol F; Wagner K; Göhring G; Schlegelberger B; Heuser M; Ganser A; Morgan MA
    Ann Hematol; 2014 Jun; 93(6):977-82. PubMed ID: 24737308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Qian J; Yao DM; Lin J; Qian W; Wang CZ; Chai HY; Yang J; Li Y; Deng ZQ; Ma JC; Chen XX
    PLoS One; 2012; 7(9):e45760. PubMed ID: 23029227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins.
    Lee SC; Dvinge H; Kim E; Cho H; Micol JB; Chung YR; Durham BH; Yoshimi A; Kim YJ; Thomas M; Lobry C; Chen CW; Pastore A; Taylor J; Wang X; Krivtsov A; Armstrong SA; Palacino J; Buonamici S; Smith PG; Bradley RK; Abdel-Wahab O
    Nat Med; 2016 Jun; 22(6):672-8. PubMed ID: 27135740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Prognostic significance of different IDH mutations and accompanying gene mutations in patients with acute myeloid leukemia].
    Wu RY; Xie XS; Wei Y; Jang ZX; Chen DD; Sun H; Wan DM; Liu YF; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):39-44. PubMed ID: 33677867
    [No Abstract]   [Full Text] [Related]  

  • 25. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases.
    Schoch C; Schnittger S; Klaus M; Kern W; Hiddemann W; Haferlach T
    Blood; 2003 Oct; 102(7):2395-402. PubMed ID: 12805060
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and Biological Implications of Mutational Spectrum in Acute Myeloid Leukemia of FAB Subtypes M0 and M1.
    Cheng Z; Dai Y; Pang Y; Jiao Y; Zhao H; Wu S; Zhang L; Zhang Y; Wang X; Wang L; Ma D; Qin T; Hu N; Zhang Y; Hu K; Zhang Q; Shi J; Fu L
    Cell Physiol Biochem; 2018; 47(5):1853-1861. PubMed ID: 29961066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
    Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SF3B1 mutation is a rare event in Chinese patients with acute and chronic myeloid leukemia.
    Yang J; Qian J; Yao DM; Qian SX; Qian W; Lin J; Xiao GF; Wang CZ; Deng ZQ; Ma JC; Chen XX
    Clin Biochem; 2013 May; 46(7-8):701-3. PubMed ID: 23395771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis.
    Han X; Li W; He N; Feng P; Pang Y; Ji C; Ma D
    Clin Chim Acta; 2018 Apr; 479():25-37. PubMed ID: 29309772
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.
    Zhou JD; Yang L; Zhu XW; Wen XM; Yang J; Guo H; Chen Q; Yao DM; Ma JC; Lin J; Qian J
    Int J Clin Exp Pathol; 2015; 8(5):5336-44. PubMed ID: 26191235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
    Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
    J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
    Senapati J; Urrutia S; Loghavi S; Short NJ; Issa GC; Maiti A; Abbas HA; Daver NG; Pemmaraju N; Pierce S; Chien KS; Sasaki K; Kadia TM; Hammond DE; Borthakur G; Patel K; Ravandi F; Kantarjian HM; Garcia-Manero G; DiNardo CD
    Blood; 2023 Nov; 142(19):1647-1657. PubMed ID: 37441846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutational analysis of splicing machinery genes SF3B1, U2AF1 and SRSF2 in myelodysplasia and other common tumors.
    Je EM; Yoo NJ; Kim YJ; Kim MS; Lee SH
    Int J Cancer; 2013 Jul; 133(1):260-5. PubMed ID: 23280334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype.
    Chao HY; Jia ZX; Chen T; Lu XZ; Cen L; Xiao R; Jiang NK; Ying JH; Zhou M; Zhang R
    Int J Lab Hematol; 2012 Oct; 34(5):502-9. PubMed ID: 22494415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative analysis of prognostic factors in Chinese core binding factor leukemia.
    Wang D; Qiao C; Xiao M; Geng Z; Shang Z; He J; Huang M; Yang Y; Zhang N; Liu Y; Li J; Li C; Zhou J
    Biochem Biophys Res Commun; 2012 Nov; 428(3):411-5. PubMed ID: 23107788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia.
    Marková J; Michková P; Burčková K; Březinová J; Michalová K; Dohnalová A; Maaloufová JS; Soukup P; Vítek A; Cetkovský P; Schwarz J
    Eur J Haematol; 2012 Feb; 88(2):128-35. PubMed ID: 21967546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical manifestation of the SRSF2 gene mutation in Chinese patients with chronic myelomonocytic leukemia.
    Sun C; Zhang S; Qiao C; Yang X; Li J
    Chin Med J (Engl); 2014; 127(24):4215-9. PubMed ID: 25533824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
    Arbab Jafari P; Ayatollahi H; Sadeghi R; Sheikhi M; Asghari A
    Hematology; 2018 Dec; 23(10):778-784. PubMed ID: 29757120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.